Solana Co quarterly report, Q2 FY2018

Vollständiges Dokument

Filing summary

Filing identity: The request identifies Solana Co, but the supplied Form 10-Q is for Helius Medical Technologies, Inc. This summary reflects the filing text, not the company named in the request.

Business context and reporting period

The unaudited 10-Q covers the quarter and six months ended June 30, 2018. Helius is a pre-revenue neurotechnology company developing the investigational PoNS device for neurological rehabilitation. Amounts below are in U.S. dollars; financial-statement amounts are in thousands unless otherwise indicated.

Key financial results and position

  • Revenue: None in Q2 2018 or the first half of 2018; the comparable 2017 periods also had no revenue. Gross margin is not applicable.
  • Q2 results: Operating expenses were $11.8 million, including R&D of $2.9 million and G&A of $8.9 million. Operating loss was $11.8 million; net loss was $17.8 million, or $0.78 per basic and diluted share.
  • First-half results: Operating expenses were $16.5 million (R&D $5.5 million; G&A $11.1 million). Operating loss was $16.5 million and net loss was $19.0 million, or $0.88 per basic share and $0.90 per diluted share.
  • Cash flow, first half: Operating cash used was $11.1 million and investing cash used was $0.2 million; financing provided $21.7 million. Cash increased $10.4 million to $16.0 million.
  • Liquidity and liabilities: Current assets were $16.7 million and current liabilities $29.1 million, including $15.6 million of derivative liabilities and $10.6 million of stock-based compensation liability. The company reported working capital of $13.8 million using its definition, which excludes those two liabilities. No debt balance is identified in the supplied balance sheet.
  • Equity: Stockholders’ deficit was $12.1 million. Shares outstanding were 23.38 million at June 30, 2018.

Material changes versus comparable periods

  • Q2 net loss rose from $5.7 million in 2017 to $17.8 million in 2018; first-half net loss increased from $11.4 million to $19.0 million.
  • R&D declined year over year as the registrational clinical trial and device design work progressed or concluded. G&A increased substantially, primarily due to higher stock-based compensation and professional fees.
  • Cash used in operations increased from $9.3 million to $11.1 million in the first half. Financing cash inflow rose to $21.7 million, including the April 2018 public offering and exercises of options and warrants.
  • A change in functional currency from Canadian dollars to U.S. dollars effective April 1, 2018 led to reclassification and remeasurement of certain warrants and options. The resulting fair-value accounting materially affected reported expenses and liabilities.

Outlook, commentary, risks, and unusual items

  • Management intended to submit a PoNS marketing-authorization application to the FDA in Q3 2018, after pre-submission discussions, and planned applications in Canada, Europe, and Australia in the second half of 2018. These were plans, not reported approvals.
  • Commercial launch planning was ongoing, with an initial U.S. and Canadian focus on cash-pay and workers’ compensation customers. The company also planned clinical experience programs at rehabilitation centers.
  • Management stated that the company had never generated product revenue and expected continued operating losses and cash outflows. The filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern; further capital may be needed, with no assurance it can be raised on acceptable terms.
  • Q2’s $6.2 million derivative fair-value loss and first-half $6.7 million stock-based compensation expense were substantially affected by noncash valuation and classification effects. Management noted that options covering 2.63 million shares were modified in August 2018 to change exercise prices from CAD to USD; it expected reclassification from liabilities to equity in Q3.
  • The filing cites risks involving FDA authorization, commercialization and manufacturing, future financing, foreign-exchange exposure (which is not hedged), Nasdaq listing requirements, and possible U.S. government rights or a $2.0 million contractual penalty if specified PoNS milestones are not met by December 31, 2021. Management characterized the penalty payment as remote based on the amendment described.
  • After quarter-end, the company completed its reincorporation from Wyoming to Delaware on July 20, 2018. Management reported disclosure controls and procedures were effective at June 30, 2018 and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  • Confirm the issuer: the supplied filing is Helius Medical Technologies, Inc., not Solana Co.
  • Check subsequent FDA submission and review milestones, and whether planned international applications were filed.
  • Assess cash runway against operating cash use, planned commercialization costs, and management’s stated need for additional funding.
  • Review the warrant and option terms, fair-value assumptions, August 2018 modifications, and the effect of any subsequent reclassification or exercise.
  • Verify progress toward the December 31, 2021 U.S. government availability milestone and the related contractual and intellectual-property consequences.